Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G STUDYING .12% CHLORHEXIDINE MOUTHRINSE FOR GINGIVITIS

Executive Summary

P&G STUDYING .12% CHLORHEXIDINE MOUTHRINSE FOR GINGIVITIS, Procter & Gamble researchers reported at the American Assn. of Dental Researchers recent annual meeting in Washington, D.C. Investigators O. P. Sturzenberger, et al, reported the results of a six-month clinical study in which an unspecified number of patients were given prophylactic treatment and then put on a program of oral mouthrinses, receiving either a .12% chlorhexidine solution or a placebo. "The average reduction in gingivitis severity obverved in this study was 45%," an abstract of the study reports. Sturzenberger, et al, stated that a previous study had shown that "a prophylaxis [treatment] significantly reduced gingivitis severity by 45%" but that the clinical benefit "diminished over a 10-day period following the prophylaxis, at which time gingivitis severity returned to baseline levels." The researchers reported that use of chlorhexidine rinse maintained the reduced gingivitis levels for the entire six months of the study. The investigators also noted that "when the clinical population was subdivided into groups according to their initial gingivitis severity (i.e., number of gingival bleeding sites), those subjects with the most gingival bleeding showed a 61% reduction in gingivitis severity compared to baseline." P&G has reportedly been studying chlorhexidine for over a decade. The ingredient is currently marketed in European oral health care products at concentrations of .2%. FDA's OTC Dentifrice and Dental Care Products panel did not consider chlorhexidine in its report. P&G researchers D.J. Moore, et al., also conducted a six-month study on 430 individuals in an attempt to determine possible side effects of chlorhexidine. Previous studies and experience in Europe showed that continued use of the ingredient could cause staining and a rise in calculus (tartar) accumulation. The study's conclusions did reveal a statistically higher accumulation of tartar, but no concurrent decrease in the effectiveness of chlorhexidine as an antimicrobial and antigingival. Furthermore, only 15% of the 430 participants developed heavy stains while 44% had no visual increase in stains, an abstract of the study said, adding that the stains that did occur were readily removable.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel